<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322149</url>
  </required_header>
  <id_info>
    <org_study_id>AT-1501-A201</org_study_id>
    <nct_id>NCT04322149</nct_id>
  </id_info>
  <brief_title>Multiple Doses of AT-1501-A201 in Adults With ALS</brief_title>
  <official_title>A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anelixis Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anelixis Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized
      monoclonal antibody antagonist to CD40LG. Approximately 54 adults with ALS will be enrolled
      into the study in the United States at up to 12 ALS treatment sites.

      Participants will be enrolled into one of three ascending doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized
      monoclonal antibody antagonist to CD40LG. Approximately 54 adults with ALS will be enrolled
      into the study in the United States at up to 12 ALS treatment sites.

      Three ascending doses of AT-1501 will be administered as an IV infusion to sequentially
      enrolling cohorts. Each participant will receive 6 bi-weekly (every other week) infusions of
      AT-1501 over an 11-week period.

      The study is estimated to take 19 weeks for participants.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Approx. 5 Months</time_frame>
    <description>Incidence of adverse events (AEs) as characterized by, changes in physical examination, vital signs, ECG, laboratory parameters, and C-SSRS from baseline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>AT-1501</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 sequential dose cohorts</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-1501</intervention_name>
    <description>AT-1501 monoclonal antibody targeting CD40LG given as an IV infusion</description>
    <arm_group_label>AT-1501</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ALS diagnosed as possible, laboratory supported probable, probable, or definite as
             defined by revised El Escorial criteria.

          2. FVC (Forced Vital Capacity) equal to or greater than 60%.

          3. No more than 24 months from diagnosis.

          4. Able and willing to give informed consent, follow trial procedures, and make multiple
             clinical site visits.

        Exclusion Criteria:

          1. Any other central or peripheral nervous system disease that may interfere with the
             evaluation of ALS or its progression.

          2. Presence of a tracheostomy, or use of permanent assistive ventilation (ventilatory
             support for 23 hours per day or more).

          3. History of malignancy within the previous 5 years, except for localized non-melanoma
             skin cancers.

          4. Abnormal function of the immune system resulting from:

               -  Clinical conditions affecting the immune system (e.g. HIV infection,
                  agammaglobulinemia),

               -  Systemic administration of corticosteroids (PO/IV/IM) at a dose equivalent to 20
                  mg/day of prednisone for more than 14 consecutive days within 90 days prior to
                  screening,

               -  Administration of anti-neoplastic and/or immunomodulating agents (e.g. TNF Î±
                  antagonists or anti-B cell antibodies) or radiotherapy within 1 year prior to
                  screening.

          5. Recipient of Stem Cell or Gene Therapy.

          6. Positive test for Hepatitis B surface antigen, Hepatitis C antibody, or HIV.

          7. History of deep venous thrombosis or pulmonary embolism.

          8. History of active substance abuse within the past 2 years;

          9. History of stroke, poorly controlled or significant cardiovascular disease, diabetes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Perrin, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Anelixis Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Bartoshevich</last_name>
    <phone>16033205141</phone>
    <email>jbartoshevich@anelixistherapeutics.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Lou Gehirg's Disease</keyword>
  <keyword>motor neuron disease</keyword>
  <keyword>motor neuron degeneration</keyword>
  <keyword>AT-1501</keyword>
  <keyword>humanized blocking antibody to CD40LG</keyword>
  <keyword>CD40LG inhibitor</keyword>
  <keyword>monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

